A case of catastrophic antiphospholipid syndrome presented with diffuse myelopathy by 源��썝二�
 
 
 
 
 
 
 
online © ML Comm 
 
 50 Copyright ⓒ 2008 The Korean Neurocritical Care Society
 
A Case of Catastrophic Antiphospholipid Syndrome Presented 
with Diffuse Myelopathy 
 
Hyun Sook Kim, MD1, Ok Joon Kim, MD, PhD1 and Won-Joo Kim, MD, PhD2 
1Department of Neurology, Pochon CHA University College of Medicine, Seongnam, Korea 
2Department of Neurology, Yonsei University College of Medicine, Yongdong Severance Hospital, Seoul, Korea 
 
Background: Antiphospholipid syndrome (APS) could present numerous clinical features associated with antiphospholipid antibodies. 
Among them, the symptom complex of predominant microvasculopathy and multiple organ failure is known as‘catastrophic’ antiphos-
pholipid syndrome (CAPS) or Asherson’s syndrome. Many precipitating factors of CAPS include trauma (either major or minor), malig-
nancies, warfarin withdrawal,“flares” of systemic lupus erythematosus etc. The antiphospholipid antibodies (aPL) mainly effect on the 
coagulation pathway, however, there are increasing evidences of multifactorial actions of aPL. Case Report: A 27-year-old woman pre-
sented with dysuria and paraparesis for one day after upper respiratory infection. Neurological examination was compatible to myelopathy 
at thoracic level. Brain and spinal MRI showed lesions on hypothalamus and diffuse spinal cord. Despite of steroid therapy, probable 
ischemic cardiomyopathy, livedo reticularis, thrombocytopenia and comatous mental status were developed. She improved partially after 
plasma exchanges. Conclusion: We present a CAPS patient with thrombotic and nonthrombotic manifestations triggered by upper 
respiratory infection. J Neurocrit Care 2008;1:50-53 
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Introduction 
 
Antiphospholipid syndrome (APS) is clinically manifes-
ted as vascular thrombosis or pregnancy morbidity. Labora-
tory test should confirm the presence of lupus anticoagulant 
(LA), anticardiolipin antibody (aCL) or anti-β2glycopro-
tein-I (β2GPI) antibody. Diagnosis of APS requires at least 
one of the clinical features and one of the laboratory findings, 
which are mentioned above.1 Antiphospholipid antibodies 
(aPL) are known to cause APS by modulating the cells in-
volved in coagulation pathway and by direct antibody effect 
on target organs.2 Recent studies made it clear that the ac-
tions of the aPL were multifactorial, and also involved effects 
on the endothelium and platelets, and possibly on neural tis-
sues and hormonal and complement pathways.3 
APS can be classified into ‘primary’ and ‘secondary’ by 
underlying etiology. Secondary APS is associated with sys-
temic lupus erythematosus (SLE) and other autoimmune di-
seases, malignancy, medication and infectious diseases. On 
the contrary, when APS occurs in patients without clinical 
or serologic evidence of SLE or other disease, the syndrome 
is defined as ‘primary’ APS.4 Aside from its etiology; the cli-
nical manifestations of APS are divided into two types. Most 
APS patients present with the so-called ‘classic’ type as ch-
ronic, relatively benign, recurrent thrombotic events invol-
ving larger vessels. And some APS patients present with the 
‘catastrophic’ type, which is also described as ‘Asherson’s 
Syndrome’.5 This form starts with acute coagulopathy and 
multiple organ failure. Through a catastrophic or devastating 
course, it often ends up the fatality.6 Catastrophic antiphos-
pholipid syndrome (CAPS) is induced by infection, surgical 
operation, major or minor trauma, invasive procedures and 
warfarin withdrawal.7 We report a CAPS patient presented 
with diffuse myelopathy triggered by upper respiratory tract 
infection. 
 
Case 
 
A 27-year-old unmarried woman with no significant past 
medical or family history presented with dysuria, paraparesis 
and hypoesthesia of lower extremities for one day. One week 
before, she took 3.0 gram of cefazolin and 750 mg of ami-
kacin per a day for mild fever, cough, coryza and sputum. No 
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preceding skin rash had existed. Blood pressure was 120/70 
mmHg, and physical examination revealed neck stiffness. 
On neurological examination, mental status, mental functions, 
cranial nerves functions and cerebellar functions were all 
normal. There was no decreased visual acuity neither visual 
blurring. Motor and sensory examination revealed MRC G1 
on bilateral lower extremities and hypoesthesia below T11 
spinal cord level. Knee and ankle jerks were absent. No pa-
thologic reflexes existed. Spinal cord MRI showed diffuse 
myelopathy in cervical and thoracic spine reaching to the 
upper medulla (Fig. 1). Routine laboratory tests showed 
normal results. On CSF study, the results were opening pres-
sure 230 mmCSF, WBC count 2,400/mm2 (poly 95%), RBC 
5,500/mm2, protein 230 mg/dl, glucose 48 mg/dl and serum 
glucose 164 mg/dl. Viral markers for Epstein-Barr virus and 
mycoplasma were negative, as were H & E stain and culture 
for bacteria as well as AFB stain, culture and PCR for Myco-
bacterium tuberculosis. Oligoclonal band was absent and IgG 
index was within normal range. Under the diagnosis of my-
elitis, IV methylprednisolone started at a dose of 1,000 mg 
per a day for five days, and IV ceftriazone 4 gram and vanco-
mycin 2 mg per a day injected for two weeks. However, there 
was no improvement of the neurological findings. 
On the 7th hospital day, CSF showed that opening pressure 
had fallen to 220 mmCSF, WBC counts to 20/mm2 (l ympho 
95%), RBC to 480/mm2 and that protein and glucose levels 
were normalized. Brain MRI showed increased T2 signal 
intensity at the hypothalamus (Fig. 2). Hemoglobin level 
was 10.9 g/dl and platelet count was 129,000/ul. ESR was 
57 mm/hr. direct and indirect Coombs tests were negative. 
Activated PTT was normal and VDRL was negative. On 
routine chemistry test, serum SGOT and SGPT were eleva-
ted up to 255/167 IU/l and lactate dehydrogenase (LDH) 
was 1,810 unit/l with elevated LDH4 fraction. Systolic blood 
pressure was 80 mmHg. On echocardiography, ejection frac-
tion was 60% and there was no vegetation, or intracardiac 
thrombi. Sinus tachycardia and nonspecific T-wave abnor-
mality on EKG, as well as elevated levels of cardiac enzymes 
[Creatine kinase (CK) 232 IU/l, CK-MB 9.95 ng/ml, Tropo-
nin-T 0.24 ng/ml], suggested cardiac ischemia. 
On the 28th hospital day, platelet count was decreased to 
22,000/ul and purpuric skin eruption with reticular pattern 
developed on the bilateral lower extremities. Somatic sensory 
levels ascended to T6 spinal cord level and motor weakness 
deteriorated to MRC G0 on bilateral lower extremities. On 
the 30th hospital day, comatose mental status and absent 
brain stem reflexes were developed. Under the impression 
of progression to the brain stem, six courses of plasma ex-
change (50 mL/kg every other day, replaced with serum al-
bumin) were applied. After then, mental status, thrombo-
cytopenia, and skin lesions were improved. However, limited 
horizontal motions of extraocular muscles (‘one and a half 
syndrome’) remained and she could not breathe adequately 
during sleep, despite voluntary respiration remained intact 
(‘Ondine’s curse’). IgG isotype (63.5 GPL), IgM isotype 
(41.4 MPL) of aCL, and anti-RNP (14.4 AU) were all posi-
tive and rheumatic factor was 31.5 IU/ml. ANA was weakly 
positive. LA and anti-Ro/La were negative. Serum C3 and 
C4 were decreased. 
After oral warfarin and steroid therapy were initiated, 
brainstem functions were restored but myelopathic sequalae 
persisted, and there has been no recurrence over 3 years. 
 
Discussion 
 
In this case, differential diagnoses were acute disseminated 
encephalomyelitis (ADEM), systemic vasculitis involving 
central nervous system, multiple sclerosis (MS), neuromy-
elitis optica (NMO), spinal cord infarction, spinal arterio-
venos malformation (AVM) and SLE. Patients with ADEM 
do not develop the thrombocytopenia, livedo reticularis, car-
diac and hepatic dysfunctions, which were evident in this 
case. In systemic vasculitis involving central nervous system, 
brain lesions must be compatible with multiple infarcts in 
FIGURE 1. Whole spine
MRI demonstrates dif-
fuse myelopathy in cer-
vical and thoracic spine
reaching to the upper
medulla. 
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more than one vascular territory. The MS was less likely 
because of absent oligoclonal band, normal level of IgG 
index, multiorgan failure and inconsistent brain and spinal 
cord lesions on MRI. In this case, optic neuropathy, which is 
the principal features of NMO, was not evident and systemic 
symptoms other than brainstem and spinal cord lesions did 
not compatible with NMO. The diffuse spinal involvement 
distinguished this patient from spinal infarction or spinal 
cord AVM, because it did not fit to the vascular territory of 
the spinal cord. The patient’s past medical history, laboratory 
findings and clinical features did not fulfill the diagnostic 
criteria of SLE of American Rheumatology Association.8 Con-
sequently, the diagnosis of this patient was CAPS (Asherson’s 
syndrome) as evidenced by myelopathy, thrombocytopenia, 
positive aCL, cardiac dysfunction, hepatic dysfunction and 
livedo reticularis triggered by previous upper respiratory tract 
infection. 
Acute disseminated coagulopathy and vasculopathy asso-
ciated with aPL are thought to be the major pathophysio-
logy of CAPS. In these patients, clinical findings are acute 
progressive multiple vascular occlusions involving more than 
three organs and often results in death.6 The most frequent 
predisposing factor is infection; trauma and invasive proce-
dures, anticoagulation problems and tumors follow.7 Because 
infection is the most frequent predisposing factor of CAPS, 
recent studies suggest ‘molecular mimicry’ theory for infec-
tious triggering of APS. Viral proteins are found to have 
sequence homology to the GDKU and GDKU2 proteins, 
which are the major phospholipids binding sites on β2GPI, 
and the aPL antibodies are mainly directed to β2GPI.9 Then, 
viral infection may induce pathogenic antiphospholipids and 
precipitate APS.10 
The pathogenic mechanisms mediating APS have not yet 
been completely established. Over the ensuing few years, it 
became clear that the actions of aPL were multifactorial. The 
first mechanism of aPL is their effects on the coagulation 
pathway. Vascular thromboses occurs by the inhibited pro-
duction of prostacyclin, suppression of protein C pathway 
and antithrombin III activity, decreased fibrinolysis, activated 
platelet aggregation and activation of prekallikrein. Regar-
ding thrombotic events, recent studies have emphasized the 
functions of cells involving coagulation homeostasis. Endo-
thelial cells play a major role in the paradox of the prolon-
gation of coagulation assays in vitro and the association with 
thrombophilic diathesis in vivo. Experimentally, coagulation 
is precipitated with damaged, rather than intact, endothelial 
cells. Endothelial cell apoptosis and thrombotic vasculopathy 
are induced by activated endothelial cells consisting of co-
factors (β2GPI or prothrombin) of antiphospholipid antibody 
complex.11 There is increasing evidence that antithrombin 
antibodies and anti β2GPI antibodies may play other impor-
tant roles in thrombotic events.12 
The pathogenesis of nonthrombotic events may be the im-
mune-mediated responses such as direct antigen-antibody 
response, complement-mediated and cytokine-mediated reac-
tions, rather than aPL associated thrombosis.13,14 Among the 
nonthrombotic APS events, chorea, transverse myelitis, epi-
lepsy and multiple sclerosis-like syndrome represent the 
central nervous system involvement. Particularly, direct in-
teraction between aPL and cellular elements of the central 
nervous system seems to be a more probable mechanism and 
presence of unrecognized myelin-specific antibody is also 
suggested in transverse myelitis and multiple sclerosis-like 
syndrome.14 Furthermore, transverse myelitis appeared in 
the viral peptide or anti-β2GPI antibody -induced APS mice 
model.9 
In this case, thrombotic and nonthrombotic mechanisms 
occurred in one event. This finding suggested that thrombotic 
and nonthrombotic mechanisms could not be separated each 
other and more comprehensive pathogenic hypothesis should 
be considered. This also suggests that while infection may 
trigger the catastrophic events, it is the underlying genetic, 
FIGURE 2. Brain MRI demonstrates
the increased signal intensity in T2-
weighted image, in which there is 
no contrast enhancement, at the hy-
pothalamus and medulla oblongata.
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immunologic and other individual factors of patient back-
ground that are much more important in disease progress. 
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